As known, the anti-obesity drug rimonabant (CB1 inverse agonist) entered in the market in 2006 showing great efficacy in reducing adiposity, leptin, and insulin resistance as well as improving glucose and lipid metabolism (Quarta and Cota, 2020). Here, CNR1 is linked to obesity disorder.